ClinicalTrials.gg
CompletedNCT03289234Updated Jul 15, 2026Results posted

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

A Phase 1 interventional study of MCI-186 in Hepatic Impairment and Healthy, sponsored by Shionogi. Completed at 2 sites in Japan. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2016, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate Hepatic impairment compared to subjects with normal hepatic function

02

Conditions studied

  • Hepatic Impairment
  • Healthy
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects

  • Able to provide written to participate in this study after reading the ICF
  • Subjects is able to understand and willing to cooperate and comply with the Protocol restrictions and requirements.
  • A body weight of ≥45 kg in males or ≥40 kg in females and a ranging from 18 to 30 kg/m2

Hepatic impaired subjects (in addition)

  • A score of 5 or 6 for subjects with mild hepatic impairment, and between 7 and 9, inclusive, for subjects with moderate hepatic impairment
  • Chronic and stable hepatic impairment

Healthy subjects (in addition)

  • Subject with normal hepatic function
  • Good health and free from illness or disease

Exclusion criteria

Exclusion Criteria:

All subjects

  • Presence or history of severe allergy to food, or any medicinal product or relevant that is of clinical significance
  • Subjects were previously administered MCI-186.
  • Positive urine drug screen (if not due to concomitant medication) or alcohol test
  • History of drug abuse
  • Presence of alcohol abuse
  • Presence of active infection requiring antibiotics
  • Positive test for (HIV) antigen/antibody
  • Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>160 mmHg and/or diastolic blood pressure (DBP)>100 mmHg
  • \<60 mL/min/1.73m2

Hepatic impairment subject (in addition)

  • Subjects with severe ascites

Healthy subject (in addition)

  • History or presence of any parenchymal hepatic disease
  • Positive test for surface antigen (HBsAg) and virus antibody (HCVAb)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    mild hepatic impairment

    Drug: MCI-186

  • Experimental
    moderate hepatic impairment

    Drug: MCI-186

  • Experimental
    normal hepatic function

    Drug: MCI-186

Interventions

  • 30 mg of edaravone will be administered intravenously over 60 minutes

    Also known as: Edaravone, Radicut

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

  2. AUC0-last

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

  3. AUC0-∞

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

Secondary outcomes

  1. t½

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

07

Results

Posted Feb 28, 2020

Participant flow

Participant flow — Overall Study
MilestoneMild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic Function
Started868
Completed868
Not completed000

Outcome measures

PrimaryCmax
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · ng/mL
Cmax
ng/mLMild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic Function
Cmax538.1 ± 182.3533.4 ± 88.57429 ± 44.36
PrimaryAUC0-last
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · ng*hr/mL
AUC0-last
ng*hr/mLMild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic Function
AUC0-last716.86 ± 258.3739.28 ± 146.89582.89 ± 58.33
PrimaryAUC0-∞
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · ng*hr/mL
AUC0-∞
ng*hr/mLMild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic Function
AUC0-∞727.55 ± 262.04751.52 ± 148.34594.96 ± 63.58
Secondaryt½
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · hour
t½
hourMild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic Function
t½3.14 ± 0.584.37 ± 1.95.41 ± 6.58

Adverse events

Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mild Hepatic Impairment0/8 (0%)0/8 (0%)0/8 (0%)
Moderate Hepatic Impairment0/6 (0%)0/6 (0%)1/6 (16.7%)
Normal Hepatic Function0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventMild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic Function
Chest painGeneral disorders0/81/60/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic FunctionTotal
Mean59.6 ± 11.966.2 ± 5.361.6 ± 2.762.1 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Mild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic FunctionTotal
Female2125
Male65617
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mild Hepatic ImpairmentModerate Hepatic ImpairmentNormal Hepatic FunctionTotal
American Indian or Alaska Native0000
Asian86822
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

2 sites
  • Investigational site
    Fukuoka, Japan
  • Investigational site
    Tokyo, Japan
09

References and documents

Publications

  • Nakamaru Y, Kakubari M, Yoshida K, Akimoto M, Todorovic V, Greis T, Kondo K. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning. Clin Ther. 2020 Aug;42(8):1467-1482.e4. doi: 10.1016/j.clinthera.2020.06.016. Epub 2020 Aug 14. PubMed 32800532 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Jul 2018, 20 months.

Results were first posted in Feb 2020, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 20, 2017
StartActual
Nov 16, 2016
Primary completionActual
Jul 20, 2018
CompletionActual
Jul 24, 2018
Results first posted
Feb 28, 2020
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03289234
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Sep 20, 2017
Start date
Nov 16, 2016
Primary completion
Jul 20, 2018
Completion
Jul 24, 2018
Results posted
Feb 28, 2020
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion